[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610089":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":51,"centralContacts":54,"locations":62,"responsibleParty":179,"collaborators":11,"id":181,"slug":11,"hasResults":182,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":11,"eligibilityCriteria":186,"healthyVolunteers":182,"sex":187,"minAge":188,"maxAge":11,"enrollmentInfo":189,"targetDuration":11,"studyType":192,"phases":193,"briefSummary":196,"conditions":197,"keywords":202,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,20,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL",null,[13],"Drug: BMS-986523",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Arm C",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Arm D",[13,23],"Drug: Pembrolizumab",{"label":25,"type":10,"description":11,"interventionNames":26},"Arm E",[13,27],"Drug: Cetuximab",{"label":29,"type":10,"description":11,"interventionNames":30},"Arm F",[13,31,32],"Drug: Gemcitabine","Drug: Nab-Paclitaxel",[34,39,42,45,48],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"DRUG","BMS-986523","Specified dose on specified days",[9,15,18,21,25,29],{"type":35,"name":40,"description":37,"armGroupLabels":41,"otherNames":11},"Gemcitabine",[29],{"type":35,"name":43,"description":37,"armGroupLabels":44,"otherNames":11},"Nab-Paclitaxel",[29],{"type":35,"name":46,"description":37,"armGroupLabels":47,"otherNames":11},"Cetuximab",[25],{"type":35,"name":49,"description":37,"armGroupLabels":50,"otherNames":11},"Pembrolizumab",[21],[52],{"name":5,"affiliation":5,"role":53},"STUDY_DIRECTOR",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":11,"email":59},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":61,"role":57,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[63,80,94,108,122,137,151,166],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Johns Hopkins Hospital","RECRUITING","Baltimore","Maryland","21287","United States",{"type":71,"coordinates":72},"Point",[73,74],-76.61219,39.29038,{"lat":74,"lon":73},[77],{"name":78,"role":57,"phone":79,"phoneExt":11,"email":11},"Nilofer Azad, Site 0009","410-502-2995",{"facility":81,"status":65,"city":82,"state":83,"zip":84,"country":69,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"NEXT Oncology","San Antonio","Texas","78229",{"type":71,"coordinates":86},[87,88],-98.49363,29.42412,{"lat":88,"lon":87},[91],{"name":92,"role":57,"phone":93,"phoneExt":11,"email":11},"David Sommerhalder, Site 0001","210-580-9500",{"facility":95,"status":65,"city":96,"state":97,"zip":98,"country":69,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"START Mountain Region","West Valley City","Utah","84119",{"type":71,"coordinates":100},[101,102],-112.00105,40.69161,{"lat":102,"lon":101},[105],{"name":106,"role":57,"phone":107,"phoneExt":11,"email":11},"Justin Call, Site 0007","801-907-4750",{"facility":109,"status":65,"city":110,"state":111,"zip":112,"country":69,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"NEXT Virginia","Fairfax","Virginia","22031",{"type":71,"coordinates":114},[115,116],-77.30637,38.84622,{"lat":116,"lon":115},[119],{"name":120,"role":57,"phone":121,"phoneExt":11,"email":11},"Alexander Spira, Site 0011","703-280-5390",{"facility":123,"status":65,"city":124,"state":125,"zip":126,"country":127,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"BC Cancer Vancouver","Vancouver","British Columbia","V5Z 4E6","Canada",{"type":71,"coordinates":129},[130,131],-123.11934,49.24966,{"lat":131,"lon":130},[134],{"name":135,"role":57,"phone":136,"phoneExt":11,"email":11},"Daniel Renouf, Site 0002","6048776000Ext3297",{"facility":138,"status":65,"city":139,"state":140,"zip":141,"country":127,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9",{"type":71,"coordinates":143},[144,145],-79.39864,43.70643,{"lat":145,"lon":144},[148],{"name":149,"role":57,"phone":150,"phoneExt":11,"email":11},"Albiruni Abdul Razak, Site 0010","6479709845",{"facility":152,"status":153,"city":154,"state":155,"zip":156,"country":157,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Local Institution - 0006","NOT_YET_RECRUITING","Badalona","Barcelona [Barcelona]","08916","Spain",{"type":71,"coordinates":159},[160,161],2.24741,41.45004,{"lat":161,"lon":160},[164],{"name":165,"role":57,"phone":11,"phoneExt":11,"email":11},"Site 0006",{"facility":167,"status":153,"city":168,"state":169,"zip":170,"country":157,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Local Institution - 0008","Hortaleza","Madrid","28050",{"type":71,"coordinates":172},[173,174],-3.6411,40.47444,{"lat":174,"lon":173},[177],{"name":178,"role":57,"phone":11,"phoneExt":11,"email":11},"Site 0008",{"type":180,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610089",false,"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","A Phase 1\u002F2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","Inclusion Criteria\n\n* Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).\n* Participants must, for Arm D, have a PD-L1 expression (≥50%).\n* Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the protocol defined standard of care (SoC) treatments.\n\nExclusion Criteria\n\n* Participants must not have untreated central nervous system (CNS) metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have a history of, or any evidence of, interstitial lung disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in the radiation field is permitted.\n* Participants must not have a history of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":190,"type":191},252,"ESTIMATED","INTERVENTIONAL",[194,195],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies",[198,199,200,201],"Advanced Solid Malignancies","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)",[199,200,201,203,204,205],"Pancreatic Cancer","Lung Cancer","Kirsten rat sarcoma viral oncogene homolog (KRAS)","2026-05-26",{"date":208,"type":209},"2026-05-28","ACTUAL",{"date":211,"type":209},"2025-11-25",{"date":213,"type":191},"2028-10-13",{"name":5,"class":6},8]